Ernexa Therapeutics Inc. (ERNA) · Nov 19, 2026 · Other events

Ernexa CFO gets $5,000 monthly cash pay, no strategy shift

$5,000 monthly CFO pay — $5,000 monthly cash compensation; ~$60,000 annualized

Ernexa’s latest 8-K adds $5,000 in monthly cash compensation to CFO Mark Keeley’s existing share-based consulting arrangement, without changing the company’s operating plan.

Ernexa is a preclinical synthetic allogeneic iMSC therapy company working to move its lead oncology program, ERNA-101, toward first-in-human development while building a broader cell-therapy pipeline.

The filing adds cash compensation, not operating progress. The board approved an addendum that supplements CFO Mark J. Keeley’s existing share-based compensation with $5,000 in monthly cash pay, effective November 9, 2026. 〔0〕 That is roughly $60,000 on an annualized basis—real incremental cash usage, but small relative to the company’s core clinical-development story.

The underlying CFO arrangement is otherwise unchanged. The addendum leaves the remaining consulting terms in place, so this does not represent a CFO transition, a change in strategy, or a new financing signal. 〔1〕

Bottom line: This is a routine compensation adjustment with a minor cash-burn implication, not a meaningful change to Ernexa’s preclinical-to-clinical story.

Original filing on SEC EDGAR

Ernexa CFO gets $5,000 monthly cash pay, no strategy shift | ERNA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.